Pfizer is quietly powering ahead with bold moves—acquiring major biotech players, targeting eight cancer blockbusters by 2030, and eyeing a $130B weight-loss market with a monthly injection. While Buffett and Abel haven’t jumped in, Pfizer’s 6.5% dividend, strong moat via specialty drugs, and steep valuation discount (under 10x next year’s earnings) make it a compelling hidden gem for Berkshire—and savvy investors alike.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
